There is an overlap between MSI-H/dMMR and tumours with high TMB; however, a large proportion of CRC patients with high TMB do not show defects in the MMR pathway, making TMB a more inclusive biomarker and revealing more patients who may be good candidates for immune checkpoint inhibitor therapy [50]. This evidence concerns the gene MRC1 and colorectal carcinoma.